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DARPP-32 gene is located at 17q12. Both full length  
DARPP-32 and its transcriptional splice variant (t-
DARPP) consist of seven exons where only exon 1 is 
unique in each of the two transcripts. 
Transcription 






Genomic localization of DARPP-32, with FISH using BAC clone CTD-2019C10 (Research Genetics) that contains DARPP-32, using 
fluorescent in situ hybridization (FISH) on a normal metaphase spread. Arrows indicate the green FITC hybridization signals. The 
ideogram of chromosome 17 together with the inverted DAPI banding and FISH hybridization signals on the two chromosome 17. The 
FISH signals localize to chromosome band 17q12-q21. 
 
 
PPP1R1B (protein phosphatase 1, regulatory (inhibitor) subunit 1B  El-Rifai W, Belkhiri A 





Atlas Genet Cytogenet Oncol Haematol. 2008;12(4)  326 
 
 
This schematic illustration shows the genomic structure of DARPP-32 and its transcriptional splice variant that encodes a truncated 
DARPP-32 protein (t-DARPP). The sequence length of the mRNA of DARPP-32 is 1,841 bp, including the untranslated 3' and 5' ends. 
The length of the transcriptional splice variant of DARPP-32 that encodes a truncated DARPP-32 protein (t-DARPP) is 1,502 bp. 
DARPP-32 and t-DARPP share an identical sequence from exon 2 to the 3' end. Each of them has seven exons. Each of DARPP-32 
and t-DARPP transcripts has its own unique exon 1, where exon1 in DARPP-32 includes 548 bp whereas exon1 in t-DARPP consists of 




DARPP-32 encodes a protein of 204 amino acids 
(about 32 kD), whereas t-DARPP encodes a 168 amino 
acid protein (about 28 kD). DARPP-32 contains four 
phosphorylation sites at Thr34, Thr75, Ser102, and 
Ser137, whereas t-DARPP lacks the Thr34 
phosphorylation site of DARPP-32. The schematic 
illustration, shown above, demonstrates the 
phosphorylation sites of DARPP-32 and t-DARPP 
shown in yellow color. 
Expression 
DARPP-32 protein is highly expressed in medium-
sized spiny neurons of the neostriatum. DARPP-32 was 
characterized as a major target for dopamine and 
protein kinase A signaling. Modulation of DARPP-32 
phosphorylation state provides a molecular mechanism 
for integrating signals through several 
neurotransmitters and steroid hormones that stimulate 
dopaminoceptic neurons in various regions of the brain. 
Activation of PKA or PKG leads to phosphorylation of 
DARPP-32 at Thr34 and subsequently converts 
DARPP-32 into a potent inhibitor of protein 
phosphatase-1 (PP-1). Cdk5 can also phosphorylate 
DARPP-32 at Thr75 and this converts DARPP-32 into 
a PKA inhibitor. Expression of t-DARPP in the brain 
was not reported. 
Protein and mRNA expression of both DARPP-32 and 
t-DARPP are expressed at varying levels in several 
types of normal epithelial tissues outside the brain. 
DARPP-32 and t-DARPP are over-expressed in 
carcinomas of the breast, prostate, colon, and stomach 
compared with normal tissue samples. The observation 
that DARPP-32 and t-DARPP are frequently over-
expressed in common subtypes of human cancers 
suggests that these proteins may play a role in 
tumorigenesis. The expression of t-DARPP has been 
shown to increase the AKT kinase activity and regulate 
the levels of BCL2 in cancer cells. This effect is 











DARPP-32 plays a key role in cognitive function, and 
multiple brain functions. DARPP-32 is a key mediator 
of the biochemical, electrophysiological, 
transcriptional, and behavioral effects of dopamine. In 
this respect, DARPP-32 plays a critical role in 
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dopaminoceptive neurons in the neostriatum (and likely 
in other brain regions) in signal transduction pathways 
regulated by a variety of neurotransmitters, 
neuromodulators, and neuropeptides. Abnormal 
signaling through DARPP-32 has been implicated in 
several major neurologic and psychiatric disorders. 
DARPP-32 may be involved in the pathogenesis of 
schizophrenia and plays a role in mediating the actions 
of a broad range of drugs of abuse. 
Cancers 
Oncogenesis 
Over-expression of DARPP-32 and t-DARPP are 
associated with gastric cancer, and confer a potent anti-
apoptotic function in cancer cells through a p53 -
independent mechanism that involves preservation of 
mitochondrial membrane potential and increased Bcl2 
expression levels. t-DARPP transcriptionally up-
regulates Bcl2 by an Akt-dependent mechanism 
through activation of CREB/ATF-1 transcription 
factors in gastric cancer. DARPP-32 is frequently over-
expressed in multiple human adenocarcinomas 
suggesting that DARPP-32 proteins may be important 
in tumorigenesis. Decreased expression of DARPP-32, 
however, in oral premalignant and malignant lesions 
was observed, and thereby suggested that DARPP-32 
may be a tumor suppressor in this particular 
malignancy. In addition, phosphorylation of DARPP-
32 at Thr34 or Thr75 appears to regulate breast cancer 
cell migration downstream of the receptor tyrosine 
kinase DDR1. 
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